Compare Illumina, Inc. (ILMN) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Illumina, Inc. trades at $189.79 (market cap $27.94B), while Virgin Galactic Holdings, Inc. trades at $2.68 (market cap $329.06M). The key difference: Illumina, Inc. is far larger — about 84.9× Virgin Galactic Holdings, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | SPCE | |
|---|---|---|
Market Cap | $27.94B | $329.06M |
Sector | Health | Industrials |
52-Week High | $194.33 | $7.52 |
52-Week Low | $91.00 | $2.17 |
Enterprise Value | $29.33B | $428.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Virgin Galactic (SPCE) trades at $2.58, up 0.78% on the day, amid a bearish technical outlook and deeply negative profitability. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility in the space sector, with SPCE shares reacting to broader industry movements and specific corporate actions like stock awards.
The outlook remains highly speculative, with substantial execution risks and cash burn posing challenges. Investment opportunity hinges on future commercialization success, but current fundamentals and analyst divergence suggest caution. Key risks include reliance on future funding and intense competition in the space tourism sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
